PEMBROLIZUMAB MAINTENANCE AFTER ENFORTUMAB VEDOTIN/PEMBROLIZUMAB INDUCTION IN FRONT-LINE METASTATIC UROTHELIAL CARCINOMA.

$1,959,353FY2025Defense Health AgencyDOD

The Institute For Cancer Research

Investigators